Market Overview

Nonalcoholicsteatohepatitis (NASH) Pipeline Analysis - Forecast to 2026 -


The "Nonalcoholicsteatohepatitis
(NASH) Pipeline Analysis - Forecast to 2026"
report has been
added to's offering.

This report gives comprehensive insights on the various drugs being
developed for the treatment of NASH.

The report covers all the drugs that are in various phases of
development (Discovery, Preclinical & Clinical).

The pipeline focuses on novel pharmacologic drugs & regenerative
medicines covering small molecules, antibodies, stem cell therapies,
recombinant proteins and RNA-based therapeutics, but excludes symptom
relief drugs, generic combinations and supplemental drugs.

The report also covers some of the hot targets in research for NASH
treatments and NASH related biomarkers.

Some of the key sections covered in the report are given below:

  • Epidemiology
    • In this section, epidemiology of NASH is reviewed to understand
      potential significance and impact of the disease.
    • Global & US prevalence rates.
  • Hot Targets, Mechanisms & Therapies
    • In this section, various NASH associated targets, mechanism and
      upcoming therapies are discussed. Also, covers novel targets in
      early research for NASH along with disease progression biomarkers
      associated with NASH (Inflammatory, apoptosis, fibrosis).
  • Pipeline Analysis
    • Pipeline analysis was carried to get deeper insights on various
      treatment modalities in discovery, preclinical & development
      section, pipelines from major companies were identified and
      Potential targets were reported along with Mechanism of action,
      Current development status & nature of molecule. Pipeline analysis
      by developmental stage (Discovery to Clinical development).
    • Pipeline analysis by modalities
  • Monoclonal Antibodies pipeline analysis
  • RNA-therapeutics pipeline analysis
  • Recombinant protein pipeline analysis
    • Pipeline analysis by leading players & Target analysis
    • Drug analysis based on mechanism (Anti-Inflammatory, Anti-fibrotic
      and Metabolic)

Key Topics Covered

1. Report Description

  • Causes & Symptoms
  • Diagnosis
  • Unmet Needs
  • Current Therapies

2. Hot Targets, Mechanisms & Therapies

  • Novel Disease Mechanisms & Therapies
  • Leading Targets Of NASH
  • Novel Targets Of NASH
  • Nash Biomarkers
  • Genes Involved In NASH

3. Market Data

  • Forecasting Model
  • Market Dynamics
  • Market Sizing And Peak Sales
  • NASH Deals
  • Funding Scenario

4. Pipeline Analysis

  • Development Stage
  • Leading Players
  • Molecule Type
  • Target Analysis
  • Clinical Update On Phase 3 Molecules
  • Innovative Approaches

5. Small Molecules

  • Pipeline
  • Competitive Landscape

6. Large Molecules

  • Antibodies
    • Pipeline
    • Competitive Analysis
  • Recombinant Proteins
    • Pipeline
    • Competitive Analysis
  • RNA-Based Therapy
  • Pipeline
  • Competitve Landscape
  • Pipeline

8. Other Molecules

  • Pipeline

9. NASH Drug Analysis Based On Mechanism (Clinical)

10. Major Players

  • Company Profiles
    • Overview
    • Pipeline
    • Deals

Companies Featured

  • Albireo Pharma
  • Allergan Plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb
  • Cerenis Therapeutics
  • Connexios Life Systems
  • Enanta Pharmaceuticals
  • Gilead Sciences Inc
  • NGM Biopharmaceuticals
  • Novartis AG
  • Novo Nordisk
  • Pfizer
  • Promethera Biosciences
  • Prometic Lifesciences
  • Taiwanj Pharmaceuticals
  • Terns Pharmaceuticals
  • VBL Therapeutics
  • Viking Therapeutics

For more information about this report visit

View Comments and Join the Discussion!